Home>>Signaling Pathways>> Neuroscience>> Ophthalmology>>17-phenyl trinor Prostaglandin F2α amide

17-phenyl trinor Prostaglandin F2α amide (Synonyms: Bimatoprost amide, 17phenyl trinor PGF2α amide)

Catalog No.GC41967

17-phenyl trinor Prostaglandin F2α amide is a N-desethyl metabolite of Bimatoprost.

Products are for research use only. Not for human use. We do not sell to patients.

17-phenyl trinor Prostaglandin F2α amide Chemical Structure

Cas No.: 155205-89-3

Size Price Stock Qty
1mg
$88.00
In stock
5mg
$394.00
In stock
10mg
$699.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

17-phenyl trinor Prostaglandin F2α amide (17-phenyl trinor PGF2α amide) is an F-series PG analog in which the C-1 carboxyl group has been modified to an unsubstituted amide. PG esters have been shown to have ocular hypotensive activity. PG N-ethyl amides were recently introduced as alternative PG hypotensive prodrugs. Although it has been claimed that PG amides are not converted to the free acids in vivo, studies have shown that bovine and human corneal tissue converts the amides of various PGs to the free acids with a conversion efficiency of about 10-20% relative to the hydrolysis of isopropyl esters. 17-phenyl trinor PGF2α amide would be expected to show the typical intraocular effects of latanoprost, but with the much slower hydrolysis pharmacokinetics of the PG N-amides.

Reviews

Review for 17-phenyl trinor Prostaglandin F2α amide

Average Rating: 5 ★★★★★ (Based on Reviews and 37 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17-phenyl trinor Prostaglandin F2α amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.